Barnholtz-Sloan JS et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872

Article  PubMed  Google Scholar 

Schouten LJ et al (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705

Article  PubMed  Google Scholar 

Suh JH et al (2006) Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24(1):106–114

Article  CAS  PubMed  Google Scholar 

Mehta MP et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21(13):2529–2536

Article  CAS  PubMed  Google Scholar 

Borgelt B et al (1980) The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 6(1):1–9

Article  CAS  PubMed  Google Scholar 

Wu YL et al (2013) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 24(4):993–999

Article  PubMed  Google Scholar 

Hochmair M, Holzer S, Burghuber OC (2016) Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anticancer Drugs 27(9):914–915

Article  CAS  PubMed  Google Scholar 

Hubbeling HG et al (2018) Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol 13(4):550–558

Article  PubMed  Google Scholar 

Shepard MJ et al (2019) Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg, : p. 1–8

Hendriks LEL et al (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 14(7):1244–1254

Article  CAS  PubMed  Google Scholar 

Goldberg SB et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matthew JP et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Google Scholar 

Deeks JJ et al (2019) Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions pp 241–284

Abbas W et al (2020) The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India. South Asian J Cancer 9(01):50–52

Article  PubMed  PubMed Central  Google Scholar 

Bjørnhart B et al (2022) Effect and tolerability of immunotherapy in patients with NSCLC with or without brain metastasis. Cancers 14(7):1682

Article  PubMed  PubMed Central  Google Scholar 

Bjørnhart B et al (2019) Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncologica 58(7):953–961

Article  PubMed  Google Scholar 

Chang J et al (2023) Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases. J Cancer Res Clin Oncol 149(5):1825–1833

Article  CAS  PubMed  Google Scholar 

Dudnik E et al (2016) Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 98:114–117

Article  PubMed  Google Scholar 

Frost N et al (2021) Pembrolizumab as first-line palliative therapy in PD-L1 overexpressing (≥ 50%) NSCLC: real-world results with special focus on PS≥ 2, brain metastases, and steroids. Clin Lung Cancer 22(5):411–422

Article  CAS  PubMed  Google Scholar 

Gadgeel SM et al (2019) Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung cancer 128:105–112

Article  PubMed  Google Scholar 

Gauvain C et al (2018) Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases. Lung Cancer 116:62–66

Article  PubMed  Google Scholar 

Goldberg SB et al (2020) Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 21(5):655–663

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldman JW et al (2016) P2.36: nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets): track: immunotherapy. J Thorac Oncol 11(10):S238–S239

Article  Google Scholar 

Lauko A et al (2021) Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Sci Rep 11(1):18174

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mansfield AS et al (2021) Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1–positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep 2(8):100205

PubMed  PubMed Central  Google Scholar 

Sheng J et al (2021) Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: a real-world retrospective study in China. Thorac Cancer 12(22):3019–3031

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skribek M et al (2020) Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a ‘real-life’setting. Cancers 12(12):3707

Article  PubMed  PubMed Central  Google Scholar 

 Sun L et al (2020) Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy. American Society of Clin Oncol

Tamiya M et al (2018) Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One 13(2):e0192227

Article  PubMed  PubMed Central  Google Scholar 

Tozuka T et al (2020) Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases. Thorac Cancer 11(9): 2465-2472

Zhang G et al (2020) Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. Cancer Immunol Immunother 69:399–405

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M et al (2021) Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. J neuro-oncol 152:125–134

Article  CAS  Google Scholar 

Afzal MZ, Dragnev K, Shirai K (2018) A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. J Thor Dis 10(6):3575

Article  Google Scholar 

Hou X et al (2023) Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a multicenter, open-label, single-arm, phase 2 study. J Thorac Oncol 18(6):769–779

Article  CAS  PubMed  Google Scholar 

Nadal E et al (2023) Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non–small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05). J Clin Oncol 41(28):4478

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nogami N et al (2022) IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol 17(2):309–323

Article